Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103282042> ?p ?o ?g. }
- W2103282042 endingPage "542" @default.
- W2103282042 startingPage "536" @default.
- W2103282042 abstract "Abstract Purpose: Pemetrexed is an antimetabolite that is structurally similar to methotrexate. Because nonsteroidal anti-inflammatory drugs (NSAID) impair methotrexate clearance and increase its toxicity, we evaluated the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in advanced cancer patients. Experimental Design: In two independent, randomized, crossover drug interaction studies, cancer patients with a creatinine clearance (CrCl) ≥60 mL/min received an NSAID (aspirin or ibuprofen) with either the first or the second dose of pemetrexed (cycle 1 or 2). Pemetrexed (500 mg/m2) was infused i.v. on day 1 of a 21-day cycle, and all patients were supplemented with oral folic acid and i.m. vitamin B12. Aspirin (325 mg) or ibuprofen (400 mg; 2 × 200 mg) was given orally every 6 hours, starting 2 days before pemetrexed administration, with the ninth and final dose taken 1 hour before infusion. Pemetrexed pharmacokinetics with and without concomitant NSAID treatment were compared for cycles 1 and 2. Results: Data from 27 patients in each study were evaluable for the analysis of pemetrexed pharmacokinetics. Coadministration of aspirin did not alter pemetrexed pharmacokinetics; however, ibuprofen coadministration was associated with a 16% reduction in clearance, a 15% increase in maximum plasma concentration, and a 20% increase in area under the plasma concentration versus time curve but no significant change in Vss compared with pemetrexed alone. No febrile neutropenia occurred in any patient, and no increase in pemetrexed-related toxicity was associated with NSAID administration. Conclusions: Pemetrexed (500 mg/m2) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl ≥60 mL/min) or ibuprofen (in patients with CrCl ≥80 mL/min)." @default.
- W2103282042 created "2016-06-24" @default.
- W2103282042 creator A5000961519 @default.
- W2103282042 creator A5002909668 @default.
- W2103282042 creator A5004294508 @default.
- W2103282042 creator A5011905014 @default.
- W2103282042 creator A5014441485 @default.
- W2103282042 creator A5024704744 @default.
- W2103282042 creator A5028575924 @default.
- W2103282042 creator A5035808742 @default.
- W2103282042 creator A5044651689 @default.
- W2103282042 creator A5045286901 @default.
- W2103282042 creator A5064692327 @default.
- W2103282042 creator A5077260725 @default.
- W2103282042 creator A5078389632 @default.
- W2103282042 creator A5082380296 @default.
- W2103282042 date "2006-01-15" @default.
- W2103282042 modified "2023-10-01" @default.
- W2103282042 title "Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer" @default.
- W2103282042 cites W1550111394 @default.
- W2103282042 cites W1966641649 @default.
- W2103282042 cites W1971035689 @default.
- W2103282042 cites W1979062455 @default.
- W2103282042 cites W1988007280 @default.
- W2103282042 cites W1998421342 @default.
- W2103282042 cites W2016284731 @default.
- W2103282042 cites W2073979951 @default.
- W2103282042 cites W2079100622 @default.
- W2103282042 cites W2096258335 @default.
- W2103282042 cites W2102627969 @default.
- W2103282042 cites W2112187168 @default.
- W2103282042 cites W2118270386 @default.
- W2103282042 cites W2134038857 @default.
- W2103282042 cites W2134667653 @default.
- W2103282042 cites W2156983594 @default.
- W2103282042 cites W2160924853 @default.
- W2103282042 cites W2163379812 @default.
- W2103282042 cites W2170791347 @default.
- W2103282042 cites W2406692965 @default.
- W2103282042 doi "https://doi.org/10.1158/1078-0432.ccr-05-1834" @default.
- W2103282042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16428497" @default.
- W2103282042 hasPublicationYear "2006" @default.
- W2103282042 type Work @default.
- W2103282042 sameAs 2103282042 @default.
- W2103282042 citedByCount "34" @default.
- W2103282042 countsByYear W21032820422013 @default.
- W2103282042 countsByYear W21032820422014 @default.
- W2103282042 countsByYear W21032820422015 @default.
- W2103282042 countsByYear W21032820422016 @default.
- W2103282042 countsByYear W21032820422017 @default.
- W2103282042 countsByYear W21032820422018 @default.
- W2103282042 countsByYear W21032820422019 @default.
- W2103282042 countsByYear W21032820422020 @default.
- W2103282042 countsByYear W21032820422021 @default.
- W2103282042 countsByYear W21032820422022 @default.
- W2103282042 countsByYear W21032820422023 @default.
- W2103282042 crossrefType "journal-article" @default.
- W2103282042 hasAuthorship W2103282042A5000961519 @default.
- W2103282042 hasAuthorship W2103282042A5002909668 @default.
- W2103282042 hasAuthorship W2103282042A5004294508 @default.
- W2103282042 hasAuthorship W2103282042A5011905014 @default.
- W2103282042 hasAuthorship W2103282042A5014441485 @default.
- W2103282042 hasAuthorship W2103282042A5024704744 @default.
- W2103282042 hasAuthorship W2103282042A5028575924 @default.
- W2103282042 hasAuthorship W2103282042A5035808742 @default.
- W2103282042 hasAuthorship W2103282042A5044651689 @default.
- W2103282042 hasAuthorship W2103282042A5045286901 @default.
- W2103282042 hasAuthorship W2103282042A5064692327 @default.
- W2103282042 hasAuthorship W2103282042A5077260725 @default.
- W2103282042 hasAuthorship W2103282042A5078389632 @default.
- W2103282042 hasAuthorship W2103282042A5082380296 @default.
- W2103282042 hasBestOaLocation W21032820421 @default.
- W2103282042 hasConcept C112705442 @default.
- W2103282042 hasConcept C126322002 @default.
- W2103282042 hasConcept C2776694085 @default.
- W2103282042 hasConcept C2777240266 @default.
- W2103282042 hasConcept C2777628954 @default.
- W2103282042 hasConcept C2778239845 @default.
- W2103282042 hasConcept C2779944601 @default.
- W2103282042 hasConcept C2781059491 @default.
- W2103282042 hasConcept C29730261 @default.
- W2103282042 hasConcept C71924100 @default.
- W2103282042 hasConcept C97320921 @default.
- W2103282042 hasConcept C98274493 @default.
- W2103282042 hasConceptScore W2103282042C112705442 @default.
- W2103282042 hasConceptScore W2103282042C126322002 @default.
- W2103282042 hasConceptScore W2103282042C2776694085 @default.
- W2103282042 hasConceptScore W2103282042C2777240266 @default.
- W2103282042 hasConceptScore W2103282042C2777628954 @default.
- W2103282042 hasConceptScore W2103282042C2778239845 @default.
- W2103282042 hasConceptScore W2103282042C2779944601 @default.
- W2103282042 hasConceptScore W2103282042C2781059491 @default.
- W2103282042 hasConceptScore W2103282042C29730261 @default.
- W2103282042 hasConceptScore W2103282042C71924100 @default.
- W2103282042 hasConceptScore W2103282042C97320921 @default.
- W2103282042 hasConceptScore W2103282042C98274493 @default.
- W2103282042 hasIssue "2" @default.
- W2103282042 hasLocation W21032820421 @default.